Pointed Debate: Expert Views on Injectables - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pointed Debate: Expert Views on Injectables
We bring industry experts together to discuss the importance of self-administration and what injection technologies are best suited to this cause.


Pharmaceutical Technology Europe
Volume 24, Issue 2

Q: What is your overall assessment of the future of injectable drug delivery? What emerging trends, drivers and changes do you expect to see in the coming years?

Kaufman: With the wave of biologics coming to market, several new devices, such as auto injectors, will see increased competition. One clear way that companies will differentiate themselves will be in the choice of drug delivery device. Designing, developing, producing and launching a biologic in an innovative device will not only enhance patient compliance, but could result in more revenue. For biopharmaceutical companies, the trend is clear: find the right partner, and develop devices for your biologics and future biologics now. It takes time and money, but it will be well worth it.


Charles Potter
Novara: The future is very bright. There is a steady increase in chronic diseases, but therapeutic developments are keeping pace by offering very sophisticated treatments that can be used with self-administration and injectable systems. However, there is an increasing need for differentiation and customisation of self-injection delivery solutions to help customers strengthen brand loyalty and to increase patient adherence and compliance with therapy. Device manufacturers with a broad portfolio of differentiating devices, full-service expertise, a commitment to quality-by-design and global scale are uniquely positioned to meet the needs of pharma and biotech customers, payers and healthcare professionals. Most importantly, injectable drug delivery systems afford a unique opportunity to patients with chronic disease to optimally treat their condition with minimal disruption to quality of life.

Potter: Biologics is one of the key growth areas in the pharmaceutical industry. Biologic products typically need to be injected and injection technologies will be required for these products, whether they are new products or lifecycle management strategies of existing products. I believe that there is a fantastic future for injectable drug delivery technologies. In particular, those technologies that can deliver a range of drug and vaccines, and that are suitable for self-injection and have a low cost of goods, will be used to develop products for both existing drugs and new drugs in development.

Sadowski: Pharmaceutical pipelines are increasingly reliant upon biological products and the range of therapeutic applications for biologics is expanding to chronic conditions, such as cardiovascular diseases. We are also seeing improved cancer survival rates, in part due to improved, targeted biologic therapies, which mean that cancer will be treated more often as a chronic condition using self-injected biologic therapies. Cost pressures and patient preferences will drive pharmaceutical firms to shift the administration approach from higher cost settings, such as infusion centres, to self-administration. All of this will expand the range of therapeutic applications for self-injected products, leading to greater reliance upon and advances in technologies suited to meet the needs of increasingly diverse patient circumstances.

Steven Kaufman is Marketing Director, SHL Group (Scandinavian Health Group Ltd).

Mark Novara is Worldwide Director, Strategic Marketing / Self Administration & Injectable Systems, at BD.

Charles Potter is Chief Technical Officer at Glide Pharma.

Peter Sadowski is Chief Technology Officer at Antares Pharma, Inc.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here